Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Show more...
執行長
Richard Chin
員工
63
國家
US
上市
0 Comments
分享你的想法
FAQ
Kindred Biosciences 今天的股價是多少?▼
KIN 目前價格為 $9.25 USD,過去 24 小時上漲了 +0.11%。在圖表上更密切關注 Kindred Biosciences 股價表現。
Kindred Biosciences 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Kindred Biosciences 的股票以代號 KIN 進行交易。